{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:11:54Z","timestamp":1785813114739,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3533,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1093\/annonc\/mdp508","type":"journal-article","created":{"date-parts":[[2009,11,4]],"date-time":"2009-11-04T04:25:25Z","timestamp":1257308725000},"page":"860-863","source":"Crossref","is-referenced-by-count":170,"title":["Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome"],"prefix":"10.1016","volume":"21","author":[{"given":"P.L.","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Derenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Quirini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp508_bb0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphoma. A prospective study of 361 immunophenotyped patients treated with LNH-84 regimen","volume":"1","author":"Coiffier","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V72.2.436.436","article-title":"The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype","volume":"72","author":"Lippman","year":"1988","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp508_bb0020","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.1989.7.12.1783","article-title":"Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin\u2019s lymphoma","volume":"7","author":"Armitage","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0025","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/10428190290016926","article-title":"T-cell non-Hodgkin\u2019s lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors","volume":"43","author":"Reiser","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdp508_bb0030","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-117-5-364","article-title":"Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM\/IMVP-16 regimen: a multi-center study. Kiel Lymphoma Study Group","volume":"117","author":"Siegert","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdp508_bb0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11864-004-0020-8","article-title":"Treatment of T-cell non-Hodgkin\u2019s lymphoma","volume":"5","author":"Evens","year":"2004","journal-title":"Curr Treat Options Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0040","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary cutaneous T-cell lymphoma: review and current concepts","volume":"18","author":"Siegel","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0045","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdp508_bb0050","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdp508_bb0055","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0060","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2141.1999.01139.x","article-title":"The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia","volume":"104","author":"Sallah","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdp508_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdp508_bb0075","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp508_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdp508_bb0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3816\/CLM.2004.n.009","article-title":"Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma","volume":"5","author":"Emmanouilides","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdp508_bb0090","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/sj.bjc.6602514","article-title":"Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma","volume":"92","author":"Ng","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdp508_bb0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3816\/CLM.2005.n.030","volume":"6","author":"Crump","year":"2005","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdp508_bb0100","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp508_bb0105","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X","article-title":"TNM classification of malignant tumors. A comparison between the new (1987) and the old editions","volume":"61","author":"Sobin","year":"1988","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp508_bb0110","first-page":"1860","article-title":"Report of the committee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp508_bb0115","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0120","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","article-title":"The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin\u2019s lymphoma","volume":"12","author":"Toner","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp508_bb0125","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp508_bb0130","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0135","doi-asserted-by":"crossref","first-page":"771a","DOI":"10.1182\/blood.V108.11.2727.2727","article-title":"A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma\/leukemia","volume":"108","author":"Casale","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp508_bb0140","doi-asserted-by":"crossref","first-page":"999a","DOI":"10.1182\/blood.V110.11.3409.3409","article-title":"Zanolimumab (HuMax-CD4\u2122), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma","volume":"110","author":"d\u2019Amore","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp508_bb0145","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0150","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0155","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.V112.11.1568.1568","article-title":"Final clinical results of a phase 2 NCI multicenter study or romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included)","volume":"112","author":"Bates","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp508_bb0160","first-page":"162","article-title":"Low-dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: preliminary results of a multicenter dose finding trial","volume":"19","author":"Horwitz","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp508_bb0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood.V112.11.261.261","article-title":"PROPEL: a multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"112","author":"O\u2019Connor","year":"2008","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419389495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419389495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/4\/860\/366836\/mdp508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:21:34Z","timestamp":1624519294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419389495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0923753419389495"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp508","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}